Adolore Biotherapeutics, Inc.
PrivateLast Round
Convertible Debt
May 21, 2024
Total Funding Raised
$2.5M
Momentum Score
50 /100
Company Overview
Adolore Biotherapeutics, Inc. is a biotechnology company that develops non-opioid, locally-administered gene therapies for chronic pain.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Adolore Biotherapeutics, Inc. Comps
Public and private peers based on sector, stage, and business model.
Adolore Biotherapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | May 21, 2024 | ||||
| Seed Round | Jan 25, 2024 | ||||
| Grant | Oct 3, 2023 | ||||
| Convertible Debt | Jan 13, 2022 |
Adolore Biotherapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH HEAL Initiative | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 18, 2026
Monthly visitors increased 112% MoM, reaching 2K.
- Jan 25, 2024
$1.05M raised in Seed Round.
Adolore Biotherapeutics, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Adolore Biotherapeutics, Inc.'s valuation, stock price, and market status.
